These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36958543)

  • 1. Clinical value of RANKL, OPG, IL-6 and sclerostin as biomarkers for fibrous dysplasia/McCune-Albright syndrome.
    Meier ME; Hagelstein-Rotman M; Streefland TCM; Winter EM; Bravenboer N; Appelman-Dijkstra NM
    Bone; 2023 Jun; 171():116744. PubMed ID: 36958543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of therapy with and withdrawal from denosumab in fibrous dysplasia and McCune-Albright syndrome: an observational study.
    Meier ME; Clerkx SN; Winter EM; Pereira AM; van de Ven AC; van de Sande MAJ; Appelman-Dijkstra NM
    J Bone Miner Res; 2021 Sep; 36(9):1729-1738. PubMed ID: 34076303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Denosumab Reduces Lesional Fluoride Skeletal Burden on Na[18F]F PET-CT in Patients With Fibrous Dysplasia/McCune-Albright Syndrome.
    van der Bruggen W; Vriens D; Meier ME; Smit F; Winter EM; de Geus-Oei LF; Appelman-Dijkstra NM
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2980-e2994. PubMed ID: 33788944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Denosumab use in bone fibrous dysplasia refractory to bisphosphonate: A retrospective multicentric study.
    Trojani MC; Gensburger D; Bagouet F; Cortet B; Couture G; Marcelli C; Mehsen Cetre N; Breuil V; Chapurlat R
    Bone; 2023 Sep; 174():116819. PubMed ID: 37301527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of Long-Term Bisphosphonate Therapy in McCune-Albright Syndrome and Polyostotic Fibrous Dysplasia.
    Majoor BC; Appelman-Dijkstra NM; Fiocco M; van de Sande MA; Dijkstra PS; Hamdy NA
    J Bone Miner Res; 2017 Feb; 32(2):264-276. PubMed ID: 27649526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of RANKL in breast cancer tissue in patients with fibrous dysplasia/McCune-Albright syndrome.
    Meier ME; Hagelstein-Rotman M; Majoor BCJ; Geels RES; Appelman-Dijkstra NM; Bravenboer N
    Bone; 2023 Apr; 169():116679. PubMed ID: 36652988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Denosumab in Patients With Fibrous Dysplasia Previously Treated With Bisphosphonates.
    Majoor BCJ; Papapoulos SE; Dijkstra PDS; Fiocco M; Hamdy NAT; Appelman-Dijkstra NM
    J Clin Endocrinol Metab; 2019 Dec; 104(12):6069-6078. PubMed ID: 31390018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of RANK/RANKL/OPG Pathway Is Involved in the Pathophysiology of Fibrous Dysplasia and Associated With Disease Burden.
    de Castro LF; Burke AB; Wang HD; Tsai J; Florenzano P; Pan KS; Bhattacharyya N; Boyce AM; Gafni RI; Molinolo AA; Robey PG; Collins MT
    J Bone Miner Res; 2019 Feb; 34(2):290-294. PubMed ID: 30496606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age-Related Changes and Effects of Bisphosphonates on Bone Turnover and Disease Progression in Fibrous Dysplasia of Bone.
    Florenzano P; Pan KS; Brown SM; Paul SM; Kushner H; Guthrie LC; de Castro LF; Collins MT; Boyce AM
    J Bone Miner Res; 2019 Apr; 34(4):653-660. PubMed ID: 30645769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of IL-6 in the treatment of fibrous dysplasia of bone: The randomized double-blind placebo-controlled TOCIDYS trial.
    Chapurlat R; Gensburger D; Trolliet C; Rouanet S; Mehsen-Cetre N; Orcel P
    Bone; 2022 Apr; 157():116343. PubMed ID: 35104665
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multidisciplinary care pathway improves quality of life and reduces pain in patients with fibrous dysplasia/McCune-Albright syndrome: a multicenter prospective observational study.
    Meier ME; Hagelstein-Rotman M; van de Ven AC; Van der Geest ICM; Donker O; Pichardo SEC; Hissink Muller PCE; van der Meeren SW; Dorleijn DMJ; Winter EM; van de Sande MAJ; Appelman-Dijkstra NM
    Orphanet J Rare Dis; 2022 Dec; 17(1):439. PubMed ID: 36528764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel approach for fibrous dysplasia assessment using combined planar and quantitative SPECT/CT analysis of Tc-99m-diphosphonate bone scan in correlation with biological bone turnover markers of disease activity.
    Jreige M; Hall N; Becce F; Aubry-Rozier B; Gonzalez Rodriguez E; Schaefer N; Prior JO; Nicod Lalonde M
    Front Med (Lausanne); 2022; 9():1050854. PubMed ID: 36507503
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EFFICACY AND SAFETY OF BISPHOSPHONATE THERAPY IN MCCUNE-ALBRIGHT SYNDROME-RELATED POLYOSTOTIC FIBROUS DYSPLASIA: A SINGLE-CENTER EXPERIENCE.
    Wang Y; Wang O; Jiang Y; Li M; Xia W; Meng X; Xing X
    Endocr Pract; 2019 Jan; 25(1):23-30. PubMed ID: 30383490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of zoledronic acid therapy in fibrous dysplasia of bone: a single-center experience.
    Valadares LP; de Araújo Ferreira BS; da Cunha BM; Moreira LA; Batista FGA; da Fonseca Hottz C; Magalhães GGR
    Arch Endocrinol Metab; 2022 Apr; 66(2):247-255. PubMed ID: 35420267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological Interventions Targeting Pain in Fibrous Dysplasia/McCune-Albright Syndrome.
    Tucker-Bartley A; Selen DJ; Golden E; van Gool R; Ebb D; Mannstadt M; Upadhyay J
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Denosumab for craniofacial fibrous dysplasia: duration of efficacy and post-treatment effects.
    Raborn LN; Burke AB; Ebb DH; Collins MT; Kaban LB; Boyce AM
    Osteoporos Int; 2021 Sep; 32(9):1889-1893. PubMed ID: 33772327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of antiresorptive agents in fibrous dysplasia and McCune Albright syndrome, a systematic review and meta-analysis.
    Bertin H; Moussa MS; Komarova S
    Rev Endocr Metab Disord; 2023 Dec; 24(6):1103-1119. PubMed ID: 37632645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Denosumab versus zoledronic acid in patients previously treated with zoledronic acid.
    Anastasilakis AD; Polyzos SA; Gkiomisi A; Saridakis ZG; Digkas D; Bisbinas I; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
    Osteoporos Int; 2015 Oct; 26(10):2521-7. PubMed ID: 25990355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RANKL Inhibition in Fibrous Dysplasia of Bone: A Preclinical Study in a Mouse Model of the Human Disease.
    Palmisano B; Spica E; Remoli C; Labella R; Di Filippo A; Donsante S; Bini F; Raimondo D; Marinozzi F; Boyde A; Robey P; Corsi A; Riminucci M
    J Bone Miner Res; 2019 Dec; 34(12):2171-2182. PubMed ID: 31295366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying skeletal burden in fibrous dysplasia using sodium fluoride PET/CT.
    van der Bruggen W; Hagelstein-Rotman M; de Geus-Oei LF; Smit F; Dijkstra PDS; Appelman-Dijkstra NM; Vriens D
    Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1527-1537. PubMed ID: 31875244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.